Related Experiment Video

Updated: Feb 6, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

Overexpressed D2 Dopamine Receptor Inhibits Non-Small Cell Lung Cancer Progression through Inhibiting NF-κB Signaling

Xiao-Yuan Wu1, Chen-Xi Zhang1, Li-Chun Deng2

  • 1Central Laboratory, Nanjing Chest Hospital, School of Medicine, Southeast University, Nanjing, China.

Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|August 17, 2018
PubMed
Abstract

Insights

Dopamine receptor D2 (DRD2) inhibits non-small cell lung cancer (NSCLC) progression by suppressing the NF-κB pathway. Lower DRD2 expression correlates with poorer NSCLC outcomes, suggesting DRD2 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
  • Dopamine receptor D2 (DRD2) plays a role in NSCLC progression, but its precise molecular mechanisms remain unclear.

Purpose of the Study:

  • To investigate the inhibitory role of DRD2 in lung cancer progression.
  • To elucidate the downstream signaling pathways regulated by DRD2 in NSCLC.

Main Methods:

  • DRD2 expression analysis in clinical NSCLC specimens using qRT-PCR and immunohistochemistry.
  • In vitro assays (MTT, colony formation) to assess cell proliferation.
  • Molecular mechanism investigation via luciferase assays, western blotting, and ChIP assays.
  • In vivo validation using a murine NSCLC model.

Main Results:

  • DRD2 expression was significantly lower in NSCLC tissues compared to normal lung tissues.
  • Reduced DRD2 levels correlated negatively with tumor size, TNM stage, and patient survival.
  • DRD2 inhibition promoted NSCLC cell proliferation by activating the NF-κB signaling pathway.
  • DRD2 overexpression suppressed tumor cell growth in vitro and inhibited tumorigenesis in vivo.

Conclusions:

  • DRD2 acts as a tumor suppressor in NSCLC.
  • DRD2 exerts its function by inhibiting the NF-κB signaling pathway.
  • DRD2 represents a potential therapeutic target for NSCLC patients, particularly those with high DRD2 expression.
Keywords:
DRD2GrowthNF-κB signaling pathway Clinic outcomeNSCLCProliferation

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

6.0K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.9K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.3K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K